Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

A Study to Test Combination Treatments in People With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)

Complete title: A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung)

Research Study Number 20161065
Principal Investigator Laura Chow
Phase II

Research Study Description

The purpose of this study is to determine whether nivolumab in combination with other therapies is more effective than nivolumab alone in people with advanced lung cancer.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 20161065
Contact Seattle Cancer Care Alliance Intake Office
Telephone 800-804-8824 / 206-606-1024

Keywords: Lung Cancer; Solid Tumors; Neoplasms; Lung Carcinoma, Non-Small-Cell (NSCLC); Carcinoma, Bronchogenic; Neoplasms, Bronchial; Neoplasms, Respiratory Tract; Neoplasms, Thoracic

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials